Inteliquet – The Effect of COVID on Clinical Trials

Marie E. Lamont, President and Chief Operating Officer at Inteliquet™, a leader in clinical trial matching, discusses the impact COVID has had on clinical trials and how companies have leveraged advanced technology tools to further research, improve patient recruitment, and use AI and Machine Learning to recognize behaviors and patterns to constantly improve on the data collection process overall.

Marie E. Lamont is responsible for the overall vision and operations of Inteliquet. With the goal of providing patients and physicians access to the latest and best treatment options and care available, she helps commercialize Inteliquet’s offerings of intelligent technology, insights, and services to improve the clinical trial process, research, and translational medicine. With more than 25 years as a global biotech leader, Marie has significant commercial and operational expertise. She has held senior leadership positions in many areas focusing on corporate strategic planning and analytics, commercial operations, finance and accounting, patient services, and payer contracting and reimbursement. Prior to Inteliquet, Marie headed up an executive consulting and advisory firm for the life science and technology industries that advised companies on commercialization and integration planning, M&A support, and global market expansion. Before her consultancy, Marie was President of the Patient Services Business at Dohmen Life Science Services (DLSS), which was subsequently sold and is now part of EVERSANA (a provider of global services to the life science industry). She directed all aspects of the unit and was responsible for improving the client and patient focus by shoring up the underlying infrastructure, as well as improving patient support and employee engagement. She also was heavily involved in the success of DLSS’s brand positioning, strategic road mapping, sales business development, and patient journey adoption, along with targeting analytics for key initiatives. Prior to DLSS, Marie was Global Head of Business Strategy and Commercial Operations for Rare Disease at Sanofi Genzyme. She had stewardship for the $2.9B business where annual operating profit improved at a rate greater than revenue. As a member of the senior leadership team, she was tasked with decision analytics and support as well as bringing together disparate groups and functions into a cohesive, comprehensive global unit. While reestablishing a Rare Disease global strategy, she worked to align efforts with a range of functions, including R&D, Biologics Manufacturing, and Medical/Regulatory Affairs. She also helped to lead humanitarian programs that provided free therapy for more than 1,100 patients suffering from rare diseases in emerging markets. Prior to this position, she held several senior operational and finance roles. She took on the assignment of Vice President of Integration for Finance and Accounting following the Sanofi acquisition. Before this assignment, she was Vice President of Operations & Finance for the International Group where the business grew from $100M in 2002 to $2B at time of the Sanofi acquisition. She guided the operational strategy for the international infrastructure on a regional and country basis for the Oncology, Transplant, Renal, Biosurgery, and Rare Disease Business Units. Before this role, she directed Corporate Financial Planning & Analysis and Strategic Planning. Marie holds a bachelor’s degree in Business from Saint Michael’s College, and attended Harvard Business School and Kellogg Executive Education programs. She lives in the St. Louis area.

Liked it? Take a second to support healthprofessionalradio on Patreon!


Leave a Reply

You must be logged in to post a comment.